Literature DB >> 28350064

SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.

Kengo Okamoto1, Yuji Tanaka1, Makoto Tsuneoka1.   

Abstract

Regulation of rRNA transcription is an important factor for control of cell proliferation. We previously found that the JmjC domain-containing demethylase KDM2A reduces H3K36me2 in the rRNA gene promoter and rRNA transcription under starvation, which results in suppression of cell proliferation. The KDM2A gene also produces another protein product, SF-KDM2A, which lacks a JmjC domain and has no demethylase activity. As yet, the function of SF-KDM2A is not clear. Recently, it was reported that KDM2A was frequently amplified and that elevated expression of KDM2A was significantly associated with short survival of breast cancer patients. SF-KDM2A was more abundant than full-length KDM2A in a subset of breast cancers. In the present study, we report that SF-KDM2A localized in nucleoli and bound to the rRNA gene promoter in breast cancer cells. Overexpression of SF-KDM2A stimulated the transcription of rRNA. While the zf-CXXC domain was required for SF-KDM2A binding to the rRNA gene promoter, SF-KDM2A with mutations in the zf-CXXC domain lost the binding to the rRNA gene promoter and did not stimulate rRNA transcription. Knockdown of SF-KDM2A reduced rRNA transcription and cell proliferation. When SF-KDM2A was overexpressed, a transcriptionally repressive mark, H4K20me3, in the rRNA gene promoter was specifically reduced in a zf-CXXC domain-dependent manner, and knockdown of SF-KDM2A increased the H4K20me3 level. Taken together, these results demonstrate that SF-KDM2A binds to the rRNA gene promoter, reduces the H4K20me3 level, and activates rRNA transcription, suggesting that the stimulation of rRNA transcription by SF-KDM2A may contribute to tumorigenesis in breast cancer.

Entities:  

Year:  2017        PMID: 28350064     DOI: 10.3892/ijo.2017.3908

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  A demethylation deficient isoform of the lysine demethylase KDM2A interacts with pericentromeric heterochromatin in an HP1a-dependent manner.

Authors:  Dijana Lađinović; Jitka Novotná; Soňa Jakšová; Ivan Raška; Tomáš Vacík
Journal:  Nucleus       Date:  2017-08-17       Impact factor: 4.197

2.  Lysine-specific demethylase 2A enhances binding of various nuclear factors to CpG-rich genomic DNAs by action of its CXXC-PHD domain.

Authors:  Shiro Iuchi; Joao A Paulo
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

3.  KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells.

Authors:  Kengo Okamoto; Yuji Tanaka; Sachiko Ogasawara; Chikashi Obuse; Jun-Ichi Nakayama; Hirohisa Yano; Makoto Tsuneoka
Journal:  Oncotarget       Date:  2019-07-30

Review 4.  KDM2A/B lysine demethylases and their alternative isoforms in development and disease.

Authors:  Tomáš Vacík; Dijana Lađinović; Ivan Raška
Journal:  Nucleus       Date:  2018       Impact factor: 4.197

5.  HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis.

Authors:  Chuanhong Zhong; Bei Tao; Xianglong Li; Wei Xiang; Lilei Peng; Tangming Peng; Ligang Chen; Xiangguo Xia; Jian You; Xiaobo Yang
Journal:  Cell Death Dis       Date:  2022-02-18       Impact factor: 8.469

6.  KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.

Authors:  Xinling Liu; Jiaqiu Li; Zhanju Wang; Jie Meng; Aihong Wang; Xiaofei Zhao; Qilu Xu; Zhen Cai; Zhenbo Hu
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

7.  Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.

Authors:  Yilong Ai; Siyuan Wu; Chen Zou; Haigang Wei
Journal:  J Cell Mol Med       Date:  2021-06-12       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.